Swine Flu Vaccine Makers to Profit $50 Billion a Year!!
August 13, 2009
GlaxoSmithKline is preparing to sell billions worth of swine flu drugs this year. Their swine flu vaccine will be available by September, and international governments are already stockpiling large supplies of GSK's anti-viral treatment Relenza.
Worldwide sales from the two drugs are expected to be enormous, but the company rejected claims it was exploiting the pandemic.
GlaxoSmithKline has also developed an anti-viral face mask, which is expected to be used by people such as "front line health workers."